Pfizer Aktie

22,39 EUR -0,45 EUR -1,95 %

16:21:29

STU

26,45 USD -0,41 USD -1,51 %

16:23:09

BTT

Pfizer jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.132,35 Mrd. EUR

KGV18,31Div. Rendite6,91%

WKN852009

ISINUS7170811035

SymbolPFE

Pfizer Aktien News

Sortieren:Datum Meistgelesen

17.12.25PR NewswirePADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility

18.10.25PR NewswirePADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer

09.07.25PR NewswireEnergyX to Acquire 35,000-Acre Smackover Lithium Mineral Deposit from Pantera, Advancing Strategic Leadership in U.S. Lithium Production

WerbungPfizer-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

22.05.25PR NewswireAstellas and Pfizer's XTANDI™ (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer

26.03.25PR NewswireViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

13.02.25PR NewswireViiV Healthcare and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully finalize negotiations for APRETUDE for HIV-1 Pre-Exposure Prophylaxis

10.01.25BusinesswirePfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

06.01.25BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

20.12.24BusinesswireU.S. FDA Approves Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

19.12.24BusinesswirePfizer Invites Public to View and Listen to Webcast of February 4 Conference Call with Analysts

17.12.24BusinesswirePfizer Provides Full-Year 2025 Guidance and Reaffirms Full-Year 2024 Guidance

12.12.24BusinesswirePfizer Declares First-Quarter 2025 Dividend

10.12.24BusinesswirePfizer Invites Public to View and Listen to Webcast of December 17 Conference Call with Analysts to Provide Full-Year 2025 Financial Guidance

05.12.24BusinesswirePfizer Showcases Scientific Leadership in Breast Cancer and Blood Disorders Across More than 100 Presentations at ASH and SABCS

20.11.24BusinesswirePfizer Announces New Chief Scientific Officer and President, Research & Development

20.11.24BusinesswireEuropean Commission Approves Pfizer’s HYMPAVZI™ (marstacimab) for the Treatment of Adults and Adolescents with Severe Hemophilia A or B Without Inhibitors

14.11.24BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

04.11.24BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

29.10.24BusinesswirePfizer Reports Strong Third-Quarter 2024 Results And Raises 2024 Guidance

23.10.24BusinesswireAdvisory Committee on Immunization Practices Recommends PREVNAR 20® (20-Valent Pneumococcal Conjugate Vaccine) for Adults Aged 50 and Older

22.10.24BusinesswireU.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease

15.10.24BusinesswireTim Buckley Elected to Pfizer’s Board of Directors

11.10.24BusinesswireU.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors

10.10.24BusinesswirePfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial

09.10.24BusinesswirePfizer Declares Fourth-Quarter 2024 Dividend

08.10.24BusinesswirePfizer to Showcase Scientific Advancements in Respiratory and Other Infectious Diseases at IDWeek 2024

25.09.24BusinesswirePfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

20.09.24BusinesswirePfizer and BioNTech Receive Positive CHMP Opinion for Omicron KP.2-adapted COVID-19 Vaccine in the European Union

17.09.24BusinesswirePfizer Invites Public to View and Listen to Webcast of October 29 Conference Call with Analysts

14.09.24BusinesswirePfizer Presents Positive Data from Phase 2 Study of Ponsegromab in Patients with Cancer Cachexia

14.09.24BusinesswirePfizer’s BRAFTOVI® + MEKTOVI® Shows Long-Term Clinically Meaningful Response in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer

11.09.24BusinesswirePfizer Highlights Diverse Oncology Portfolio and Combination Approaches at ESMO 2024

28.08.24BusinesswirePfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

27.08.24BusinesswirePfizer Launches PfizerForAll™, a Digital Platform that Helps Simplify Access to Healthcare

22.08.24BusinesswirePfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine

16.08.24BusinesswirePfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

12.08.24BusinesswirePfizer Announces Top-Line Results of ABRYSVO® for RSV in Immunocompromised Adults

31.07.24PR NewswireViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1

Pfizer News

Pfizer News: auf dieser Seite finden Sie alle Pfizer News und Nachrichten zur Pfizer Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Pfizer News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Pfizer News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.